Skip to main content

Table 1 Patients’ and host/donor characteristics

From: A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia

  Haplo MUD10/10 MMUD 9/10 MUD 10/10 vs Haplo MMUD 9/10 vs Haplo
No. 265 2490 813   
Follow-up 34.2 (3–84) 35.7 (1–103) 35.8 (1–102) 0.93 0.72
Age 42.8 (18–75) 47.0 (18–76) 44.8 (18–71) <10–3 0.017
Year of Tx 2011 (07–13) 2010 (07–13) 2010 (07–13) <10–3 <10–3
Diagnosis to transplant 260 days (82–5784) 196 days (71–5793) 223d (73–4452) <10–3 0.016
Diagnosis
 AML 176 1645 510   
66% 66% 63%   
 ALL 89 845 303 0.90 0.28
34% 34% 37%   
Disease status
 CR1 159 1901 580   
60% 76% 71%   
 CR2 106 589 233 <10–3 0.001
40% 24% 29%   
Patient sex
 Male 155 1344 442   
58% 54% 54%   
 Female 110 1146 371 0.16 0.24
42% 46% 46%   
Donor sex
 Male 139 1782 490   
52% 72% 61%   
 Female 126 690 312 <10–3 0.013
48% 28% 39%   
Female to male
 No 191 2186 659   
72% 88% 82%   
 Yes 74 286 143 <10–3 <10–3
28% 12% 18%   
CMV neg to neg
 No 225 1673 577   
86% 69% 73%   
 Yes 36 754 212 <10–3 <10–3
14% 31% 27%   
Cytogenetics
 Good 29 261 68   
11% 10% 8%   
 Intermediate 168 1398 446   
63% 56% 55%   
 Poor 68 831 299 0.04 0.004
26% 33% 37%   
  1. See text for abbreviations. Cytogenetic risk at diagnosis for AML: good t(8;21), inv16 or t(16;16); poor monosomy/deletion 5 or 7, abnormalities 11q23, complex karyotype (≥3 abnormalities); intermediate all the others. Cytogenetic risk at diagnosis for ALL: adverse t(9;22) or t(4;11), intermediate all the others